A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 596
- 试验地点
- 2
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.
详细描述
In this trial, the treatment group receives BL-M07D1 and pertuzumab, while the control group receives trastuzumab, pertuzumab, and docetaxel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form and comply with the protocol requirements;
- •Female patients aged ≥18 and ≤75 years at the time of signing the informed consent form;
- •Expected survival time ≥12 weeks;
- •Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer;
- •Clear hormone receptor (HR) status;
- •Agree to provide eligible tumor tissue specimens;
- •Have at least one measurable target lesion as defined by RECIST v1.1;
- •ECOG performance status score of 0 or 1;
- •Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
- •Organ function levels must meet the requirements;
- •For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and must be non-lactating; all enrolled patients must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after treatment completion.
排除标准
- •Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks or 5 half-lives prior to the first dose.
- •Previously received ADC drug therapy with camptothecin derivatives as toxins.
- •History of severe cardiovascular or cerebrovascular disease within six months before screening.
- •Concomitant pulmonary disease resulting in severely impaired lung function.
- •History of interstitial lung disease (ILD)/interstitial pneumonia requiring corticosteroid therapy, etc.
- •QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias.
- •Diagnosed with another primary malignancy within 5 years before the first dose.
- •Newly developed deep vein thrombosis within 14 days before screening.
- •Hypertension poorly controlled by antihypertensive medications.
- •Patients with active central nervous system metastases.
- •History of severe allergic reactions to recombinant humanized antibodies or any excipient or component of BL-M07D
- •History of autologous or allogeneic stem cell transplantation or organ transplantation.
- •Previously received anthracycline therapy exceeding the prescribed dose limit.
- •Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection.
- •Severe infection within 4 weeks prior to the first use of the study drug, etc.
- •Patients with large serous cavity effusions, serous cavity effusions with obvious symptoms, or poorly controlled serous cavity effusions.
- •Receiving systemic corticosteroid therapy >10 mg/day prednisone or equivalent prior to randomization, etc.
- •Presence of severe neurological or psychiatric disorders.
- •Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent.
- •Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.
- •Subjects planning to receive or having received live vaccines within 28 days before the first dose.
- •Presence of other serious physical conditions, abnormal laboratory findings, or poor compliance that may increase the risk of participating in the study, interfere with study results, or make the patient unsuitable for participation in the study in the investigator's opinion.
研究组 & 干预措施
Docetaxel + Trastuzumab + Pertuzumab
Participants receive Docetaxel + Trastuzumab + Pertuzumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: Pertuzumab (Drug)
BL-M07D1 + Pertuzumab
Participants receive BL-M07D1 + Pertuzumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: BL-M07D1 (Drug)
BL-M07D1 + Pertuzumab
Participants receive BL-M07D1 + Pertuzumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: Pertuzumab (Drug)
Docetaxel + Trastuzumab + Pertuzumab
Participants receive Docetaxel + Trastuzumab + Pertuzumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: Trastuzumab (Drug)
Docetaxel + Trastuzumab + Pertuzumab
Participants receive Docetaxel + Trastuzumab + Pertuzumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: Docetaxel (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: Up to approximately 24 months
Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
次要结局
- Overall survival (OS)(Up to approximately 24 months)
- Objective Response Rate (ORR)(Up to approximately 24 months)
- Duration of Response (DOR)(Up to approximately 24 months)
- Disease Control Rate (DCR)(Up to approximately 24 months)
- Clinical Benefit Rate(CBR)(Up to approximately 24 months)
- Treatment Emergent Adverse Event (TEAE)(Up to approximately 24 months)
- Anti-drug antibody (ADA)(Up to approximately 24 months)